Kriya Announces $270 Million Series C Financing To Advance Fully Integrated Gene Therapy Engine
May 16, 2022•about 3 years ago
Amount Raised
$270 Million
Round Type
series c
Description
Kriya Therapeutics, Inc., a fully integrated gene therapy company pioneering novel technologies and therapeutics, today announced a $270 Million Series C financing. The financing was led by Patient Square Capital, with participation from Bluebird Ventures, CAM Capital, Dexcel Pharma, Foresite Capital, JDRF T1D Fund, Lightswitch Capital, Narya Capital, QVT, Transhuman Capital, and other undisclosed investors. Proceeds from this financing will support the advancement of Kriya’s pipeline and continued scaling of its engineering, manufacturing, and computational platforms.
Funding Insights
Based on industry dataTech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech